Exemplis Discimus 2008, 152(1):21-25

Nullam aliquet sagittis mi.

Dartura FarLancea, Norin Paesantea,c, Maranai Calhuua, Miran Mastigarb, Escara Phloxa
a Faculty of Medical Laboratory Sciences, Faculty Hospital of Kathol, Republic of Tatooine
b Faculty of General surgery, Teaching Hospital of Rishi, Republic of Mygeeto
c Institute of Tissue Engineering and Cell Therapy, Farlax University, Republic of Bogden

Background: Donec vehicula nisi ut pede ultrices suscipit.. Nunc ac tortor eget lorem condimentum imperdiet. Praesent mi risus, aliquam at, venenatis ac, bibendum at, arcu. Maecenas eget felis id tortor pulvinar molestie. Nulla leo turpis, luctus ac, suscipit vitae, condimentum vel, neque. In semper sapien sed metus vulputate consectetuer. Curabitur nibh nisl, mattis et, pulvinar non, congue ac, nulla. Donec vel est quis tortor consectetuer scelerisque.

Methods and results: Sed convallis, tortor et mollis fermentum, diam nunc vehicula nisl, a accumsan erat nulla eget massa. Nam iaculis, est vel posuere luctus, sapien ante lacinia ante, id placerat sem nibh nec lectus..

Conclusion: Nullam eu purus nec metus bibendum ullamcorper. Mauris ante odio, tincidunt vel, adipiscing in, aliquam vitae, risus. Cras urna felis, rhoncus eu, dictum quis, blandit non, enim. Curabitur vel orci vitae est iaculis congue. Fusce lectus tortor, ullamcorper non, consequat non, egestas ut, est. Praesent neque tellus, condimentum ut, rhoncus et, sollicitudin eget, risus. Maecenas sem urna, condimentum porttitor, fringilla ac, vulputate et, dolor. Morbi nisl arcu, tincidunt ullamcorper, malesuada sit amet, gravida eget, sapien.

Kľúčové slová: Curabitur in ipsum, Mauris eget augue, Cras nisl, Ut magna

Vložený: February 10, 2008; Přijatý: March 5, 2008; Uverejnené: June 1, 2008 

Zobraziť celý článok

Referencie

  1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16:481-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Institute of Health Information and Statistics of the Czech Republic. Czech health statistics yearbook 2005. IHIS CR. Prague; 2006.
  3. Institute of Health Information and Statistics of the Czech Republic, National Oncologic Registry of the Czech Republic. Cancer incidence 2004 in the Czech Republic. IHIS CR, NOR CR. Prague; 2007.
  4. Tavassoli FA, Devilee P. World health organization classifi cation of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon; 2003.
  5. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classifi cation and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23:7350-60. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006; 12:1294-300. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP et al. Molecular classifi cation of tamoxifenresistant breast carcinomas by gene expression profi ling. J Clin Oncol. 2005; 23:732-40. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  8. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Infl ammation and cancer: how hot is the link? Biochem Pharmacol. 2006; 72:1605-21. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase- 2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006; 6:181. Available from: http://www.biomedcentral.com/1471-2407/6/181 Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A. 1993; 90:2251-5. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Lang V, Symons A, Watton SJ, Janzen J, Soneji Y, Beinke S et al. ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability. Mol Cell Biol. 2004; 24:5235-48. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Beinke S, Deka J, Lang V, Belich MP, Walker PA, Howell S et al. NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol. 2003; 23:4739-52. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  13. Luciano BS, Hsu S, Channavajhala PL, Lin LL, Cuozzo JW. Phosphorylation of threonine 290 in the activation loop of Tpl2/ Cot is necessary but not suffi cient for kinase activity. J Biol Chem. 2004; 279:52117-23. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. Staff ord MJ, Morrice NA, Peggie MW, Cohen P. Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett. 2006; 580:4010-4. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  15. Cho J, Tsichlis PN. Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proc Natl Acad Sci U S A. 2005; 102:2350-5. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  16. Cho J, Melnick M, Solidakis GP, Tsichlis PN. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals. J Biol Chem. 2005; 280:20442-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  17. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK- dependent pathway. Cell. 2000; 103:1071-83. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Caivano M, Rodriguez C, Cohen P, Alemany S. 15-Deoxy- Delta12,14- prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide. J Biol Chem. 2003; 278:52124-30. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Banerjee A, Gugasyan R, McMahon M, Gerondakis S. Diverse Tolllike receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A. 2006; 103:3274-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  20. Azambuja E, Durbecq V, Rosa D, Colozza M, Larsimont D, Piccart-Gebhart M et al.. HER-2 overexpression/amplifi cation and its interaction with taxane-based therapy in breast cancer. Ann Oncol. 2007. Available from: http://annonc.oxfordjournals.org/ cgi/content/full/mdm352v1
  21. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66:3859- 68. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  22. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K et al. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specifi c manner. J Biol Chem. 2005; 280:23748-57. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  23. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 2003; 22:3855-64. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Chan H, Reed JC. TRAF-dependent association of protein kinase Tpl2/COT1 (MAP3K8) with CD40. Biochem Biophys Res Commun. 2005; 328:198-205. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol. 2005; 174:41-50. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. Tsatsanis Ch, Patriotis C, Bear SE, Tsichlis PN. The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and interleukin 2 expressions in T cell lines. Immunology. 1998; 95:3827-32.
  27. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A et al. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell diff erentiation. J Clin Invest. 2004; 114:857-66. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  28. Kikuchi T, Yoshikai Y, Miyoshi J, Katsuki M, Musikacharoen T, Mitani A et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. J Dent Res. 2003; 82:546-50. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  29. Eliopoulos AG, Dumitru CD, Wang CC, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2- dependent CREB activation signals. EMBO J. 2002; 21:4831-40. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  30. Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC et al. Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide- stimulated ERK1/2 activation in macrophages. J Biol Chem. 2006; 281:34159-70. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  31. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, Li HQ et al. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2006; 16:6067-72. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  32. Sourvinos G, Tsatsanis C, Spandidos DA. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene. 1999; 185:4968-73. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  33. Krcova Z, Ehrmann J, Eliopoulos A, Turashvili G, Klein J, Kolar Z et al. Tpl2/Cot as a new prognostic and predictive factor in breast cancer? Virchows Arch. 2007; 451:142-3.
  34. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007; 258:181-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  35. Lin VC, Jin R, Tan PH, Aw SE, Woon CT, Bay BH. Progesterone induces cellular diff erentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am J Pathol. 2003; 162:1781-7. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  36. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, Tsatsanis C. Expression of the Tpl2/Cot oncogene in human Tcell neoplasias. Mol Cancer. 2004 Dec 3;3(1): 34. Available from: http://www.molecular-cancer.com/content/3/1/34 Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  37. Wendum D, Masliah J, Trugnan G, Flejou JF. Cyclooxygenase- 2 and its role in colorectal cancer development. Virchows Arch. 2004; 445:327-33. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  38. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001; 8:97-114. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  39. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2:544-51. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  40. Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia. 2003; 8:31-43. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  41. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006; 59:382-6. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  42. Panel V, Boelle PY, Ayala-Sanmartin J, Jouniaux AM, Hamelin R, Masliah J et al. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006; 243:255-63. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  43. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A et al. COX-2 expression in DCIS: correlation with VEGF, HER- 2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005; 46:561-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  44. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004; 45:47-54. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  45. Schmitz KJ, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS et al. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol. 2006; 59:685-91. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  46. Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007; 9(1):R3. Available from: http://breast-cancer-research.com/content/ 9/1/R3 Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  47. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neuinduced breast cancer. Cancer Res. 2002; 62:5405-7. Prejsť na PubMed...
  48. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD et al. HER2/neuinduced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005; 65:10113-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah